Jazz, Anchen Strike Deal Over Generic Luvox

Law360, New York (August 30, 2010, 5:50 PM EDT) -- Jazz Pharmaceuticals Inc. has reached a settlement with Anchen Inc. and subsidiary Anchen Pharmaceuticals Inc. over their efforts to market a generic version of anxiety drug Luvox CR.

The deal includes a sublicensing agreement that will allow Anchen to manufacture and sell a generic version of Luvox — used to treat social anxiety and obsessive compulsive disorders — starting in February 2013. The settlement, which also involves Jazz subsidiary JPI Commercial LLC, was announced in Jazz’s 8-K filing with the U.S. Securities and Exchange Commission on...
To view the full article, register now.